Certara Announces Update of D360™ Scientific Informatics Software

Rhea-AI Summary

Certara, Inc. (Nasdaq: CERT) has launched D360 version 21.5, enhancing its scientific informatics software for biomedical research. This update improves efficiency in analyzing small molecules and biologic drugs, facilitating quicker, higher-confidence decision-making in drug development. Key new features include support for biologic drug sequence clustering, transformation analysis for small molecules, accelerated workflows, and advanced data visualization. D360 is utilized by over 6,000 scientists at top biopharmaceutical firms, reaffirming Certara's commitment to optimizing drug discovery processes.

Positive

• Launch of D360 version 21.5 enhances drug development efficiency.
• New features support both small molecules and biologic drugs, fostering comprehensive data analysis.
• Used by more than 6,000 scientists globally, indicating strong market adoption.
• Allows for faster decision-making in the discovery and preclinical stages.

Negative

• None.

New capabilities increase efficiency in analyzing and developing small molecules and biologic drugs

PRINCETON, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of D360 version 21.5, an industry-leading scientific informatics software for discovery scientists to integrate many data sources and analyze small molecules and biologic drugs for fast, high-confidence go/no-go decisions. This latest release increases research efficiency with comprehensive data analysis, enhanced workflows and data handling, and innovative visualization capabilities.

“State of the art intelligence technology for scientific informatics disciplines, like the D360 software, is a fundamental building block for the next generation digitalization,” said Jim Brown, president of Digital Innovation Research at research firm Tech-Clarity. “The objective is to optimize critical decision points and associated workflows in the scientific innovation lifecycle of new drug candidates within the biopharmaceutical industry.”

Certara’s D360 scientific informatics software is used globally by more than 6,000 discovery research scientists at biopharmaceutical and biotechnology companies, including five of the top 10 by research and development spend. The D360 software delivers end-to-end access to data and integrated scientific intelligence, resulting in timelier insights and greater understanding of drug candidates.

New capabilities of Certara’s D360 software include:

• Biologic drugs: Support for visual sequence clustering and HELM (Hierarchical Editing Language for Macromolecules) version 2, which is widely adopted across the industry, and enhanced capabilities for sequence-activity relationship generation
  
• Small molecules: Transformation analysis, which allows scientists to understand the effect of structural changes over a range of assays and properties
  
• Workflows: Accelerated scientific decision-making using filter capabilities and multi-valued data fields
  
• Data visualization: Visualization of multi-parameter project progression and new details viewer mode for focus on specific aspects of a dataset to accelerate scientific workflows

“With the growing drug development pipeline for large molecule biologics and new ways to analyze small molecules, we are continuously innovating our D360 software to accommodate the accelerating requirements of discovery research,” said Leif E. Pedersen, president of Software at Certara. “These new capabilities will improve the underlying scientific intelligence and allow scientists to better understand their data in a therapeutic context, ultimately leading to faster and informed decision-making during the discovery and preclinical stages of drug development.”

Learn more about D360 scientific informatics software at https://www.certara.com/data-and-informatics/d360-scientific-informatics-platform/

About Certara
Certara accelerates medicines using proprietary biosimulation software and scientific intelligence technologies that transform traditional drug discovery and development. Its clients include more than 1,650 global pharmaceutical and biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Certara Contact:
Jieun W. Choe
jieun.choe@certara.com

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media Contact:
Ariane Lovell
Finn Partners
ariane.lovell@finnpartners.com

FAQ

What is the significance of Certara's D360 version 21.5 release for stock CERT?

The D360 version 21.5 release enhances the efficiency of drug development processes, potentially increasing demand for Certara's software and positively impacting stock performance.

When was the D360 version 21.5 launched by Certara?

D360 version 21.5 was launched on November 29, 2021.

How does Certara's D360 software aid drug development?

The D360 software integrates diverse data sources, providing comprehensive analyses that facilitate faster and more informed decision-making in drug discovery.

What industries benefit from Certara's D360 software?

Certara's D360 software is utilized in the biopharmaceutical and biotechnology sectors by research scientists.

Who are the primary users of Certara's D360 software?

The software is used by over 6,000 discovery research scientists at leading biopharmaceutical and biotechnology companies.